Ascendis Pharma A/S (NASDAQ:ASND) Shares Cross Below 50-Day Moving Average of $133.44

Ascendis Pharma A/S (NASDAQ:ASND)’s share price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $133.44 and traded as low as $120.18. Ascendis Pharma A/S shares last traded at $124.99, with a volume of 340,603 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ASND shares. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, May 23rd. Wells Fargo & Company lifted their price target on Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Stifel Nicolaus started coverage on Ascendis Pharma A/S in a research report on Friday, May 31st. They issued a “buy” rating and a $200.00 price target for the company. Finally, TD Cowen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating and lifted their price target for the stock from $156.00 to $175.00 in a research report on Tuesday, June 25th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average price target of $179.00.

Ascendis Pharma A/S Stock Up 0.4 %

The stock has a market cap of $7.31 billion, a PE ratio of -13.01 and a beta of 0.63. The firm has a 50 day moving average price of $133.44 and a 200 day moving average price of $139.24.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $78,719,000. Certuity LLC acquired a new stake in Ascendis Pharma A/S in the fourth quarter worth about $270,000. GSA Capital Partners LLP acquired a new stake in Ascendis Pharma A/S in the first quarter worth about $992,000. Price T Rowe Associates Inc. MD boosted its holdings in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after acquiring an additional 336,976 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in Ascendis Pharma A/S in the fourth quarter worth about $5,779,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.